FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Gem Pharmaceuticals LLC
2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2018
3. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [NONE]
(Last)
(First)
(Middle)
C/O 1000 SKOKIE BLVD., SUITE 350, 
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

WILMETTE, IL 60091
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common stock 3,055,394.12
I
See Footnotes (1) and (2) (1) (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Gem Pharmaceuticals LLC
C/O 1000 SKOKIE BLVD., SUITE 350
WILMETTE, IL 60091
    X    
Hendricks Diane
C/O GEM PHARMACEUTICALS
200 RANDOLPH AVE.
HUNTSVILLE, AL 35801
    X    
Leo Karl
C/O GEM PHARMACEUTICALS
200 RANDOLPH AVE.
HUNTSVILLE, AL 35801
    X    
KLAUSNER ARTHUR J
ONE PALMER SQUARE
PRINCETON, NJ 08542
  X      
Pharma Investments LLC
C/O GEM PHARMACEUTICALS
200 RANDOLPH AVE
HUNTSVILLE, AL 35801
    X    

Signatures

/s/ Kim R. Tsuchimoto, Attorney-in-fact 01/08/2018
**Signature of Reporting Person Date

/s/ Kim R. Tsuchimoto, Attorney in fact 01/08/2018
**Signature of Reporting Person Date

/s/ Kim R. Tsuchimoto, attorney-in-fact 01/08/2018
**Signature of Reporting Person Date

/s/ Kim R. Tsuchimoto, Attorney-In-Fact 01/08/2018
**Signature of Reporting Person Date

/s/Kim R. Tsuchimoto, Attorney-in-fact 01/08/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This Form 3 is being filed on behalf of Gem Pharmaceuticals, LLC, an Alabama limited liability company ("Gem"), and its managers, Diane Hendricks, Karl Leo, and Arthur Klausner, and Pharma Investments ("Pharma") and its controlling shareholders, Karl Leo and Diane Hendricks (collectively, the "Reporting Persons"). The managers of Gem collectively have voting control over the securities described herein. Pharma owns a controlling share of Gem and Karl Leo and Diane Hendricks own a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein.
(2) Gem shares voting and investment power over 3,055,394.12 of the shares of common stock held by TacticGem LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.